Impact of Digital Therapeutics for the Management of Adult Patients With Diabetes: Systematic Review and Meta-Analysis of Randomized Controlled Trials
Auswirkung digitaler Therapeutika zur Behandlung erwachsener Patient:innen mit Diabetes: systematische Übersicht und Metaanalyse randomisierter kontrollierter Studien
Journal of Medical Internet Research · 08.09.2025 · 27 · e70428
DOI: 10.2196/70428 ↗Auf einen Blick
19 RCTs mit 3.264 Teilnehmenden zeigten unter digitalen Therapeutika geringere HbA1c-, FBG- und BMI-Werte als in den Kontrollgruppen. Bei Typ-2-Diabetes war der HbA1c-Effekt ausgeprägter.
Fragestellung
Wie wirksam sind digitale Therapeutika bei Erwachsenen mit Typ-1-Diabetes, Typ-2-Diabetes oder Prädiabetes?
Methode
Systematische Übersicht und Metaanalyse von RCTs; Suche in Web of Science, MEDLINE, Embase und Cochrane Library bis 30. Juli 2023; Bewertung mit Cochrane RoB 2.0.
Ergebnisse
19 Studien wurden in die Metaanalyse eingeschlossen (n=3264). HbA1c sank um WMD −0,54 % (95 %-KI −0,72 bis −0,36), FBG um −0,56 (−0,76 bis −0,37) und BMI um −0,84 (−1,23 bis −0,45).
Schlussfolgerung der Autor:innen
Digitale Therapeutika erscheinen vielversprechend für das Gesundheitsmanagement bei Diabetes und können HbA1c, FBG und BMI senken, besonders bei Typ-2-Diabetes.
Kernaussagen
- HbA1c, FBG und BMI sanken unter DTx
- Typ-2-Diabetes: stärkerer HbA1c-Effekt
- Kein signifikanter Effekt auf Gewicht oder Blutdruck
Deutsche Zusammenfassung: KI-gestützt aus dem Original-Abstract erstellt; alle Zahlen wurden automatisch mit dem Original abgeglichen. Maßgeblich ist der Original-Abstract.
Kurz gefasst
Systematische Übersicht in der Zeitschrift Journal of Medical Internet Research, online erschienen am 08.09.2025. Verfasst von Mengyu Li und 4 weiteren Autor:innen. Beteiligte Einrichtung: Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China. Hauptthemen laut MEDLINE: Diabetes Mellitus, Type 2, Diabetes Mellitus, Type 1. Die Arbeit wurde bisher 11-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar.
Themen: Diabetes mellitus
Abstract (Originalsprache)
Background
The growing approval and use of digital therapeutics (DTx) for managing chronic diseases, such as diabetes, has prompted questions about their effectiveness.
Objective
This systematic review and meta-analysis aimed to report the effectiveness of DTx interventions in the management of patients with type 1 diabetes, type 2 diabetes, and prediabetes.
Methods
Data sources, including Web of Science, MEDLINE, Embase, and the Cochrane Library, were searched from inception to July 30, 2023. We included randomized controlled trials assessing the effectiveness of DTx interventions in the health management of individuals with prediabetes and those diagnosed with type 1 diabetes and type 2 diabetes. Our primary outcomes were glycated hemoglobin (HbA1c) levels, fasting blood glucose (FBG) levels, BMI, and weight. Trials that met the eligibility criteria were scored for risk of bias using the Cochrane Risk of Bias Tool 2.0. A narrative synthesis and meta-analysis of included studies were also conducted.
Results
A total of 19 studies were included in the meta-analysis (n=3264). The DTx intervention produced a noteworthy reduction in HbA1c levels among individuals with diabetes (weighted mean difference [WMD] −0.54%, 95% CI −0.72 to −0.36), as well as decreases in FBG levels (WMD −0.56, 95% CI −0.76 to −0.37) and BMI (WMD −0.84, 95% CI −1.23 to −0.45). In addition, it contributed to the increases in low-density lipoprotein cholesterol (WMD −0.13, 95% CI −0.22 to −0.03) and triglyceride levels (WMD −0.18, 95% CI −0.34 to −0.02). Subgroup analyses revealed a beneficial impact of DTx on improving HbA1c levels in patients with type 2 diabetes mellitus (mean difference −0.66, 95% CI −0.92 to −0.41). However, this intervention did not elicit a comparable improvement in HbA1c levels for patients with type 1 diabetes mellitus (mean difference −0.45, 95% CI −0.89 to −0.00). DTx did not significantly affect weight reduction (WMD −1.07, 95% CI −2.33 to 0.20), systolic and diastolic blood pressure, total cholesterol levels, or high-density lipoprotein levels.
Conclusions
The DTx intervention holds promise for enhancing health management among individuals with diabetes, potentially attenuating HbA1c levels, FBG levels, and BMI, especially in individuals with type 2 diabetes. Trial Registration PROSPERO CRD42023473743; https://www.crd.york.ac.uk/PROSPERO/view/CRD42023473743
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Chinese Academy of Medical Sciences & Peking Union Medical College, Beijing, China.
- Hospital for Skin Diseases, Institute of Dermatology, Chinese Academy of Medical Sciences & Peking Union Medical College, Nanjing, China.
ORCID-Profile: Mengyu Li, Ying Chen, Xuehui Chen, Han Yao, Lili You
Zitieren
APA
Li, M., Chen, Y., Chen, X., Yao, H., & You, L. (2025). Impact of Digital Therapeutics for the Management of Adult Patients With Diabetes: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Medical Internet Research, 27, e70428. https://doi.org/10.2196/70428
Vancouver
Li M, Chen Y, Chen X, Yao H, You L. Impact of Digital Therapeutics for the Management of Adult Patients With Diabetes: Systematic Review and Meta-Analysis of Randomized Controlled Trials. Journal of Medical Internet Research. 2025;27:e70428. doi:10.2196/70428
BibTeX
@article{Li2025,
author = {Li, Mengyu and Chen, Ying and Chen, Xuehui and Yao, Han and You, Lili},
title = {Impact of Digital Therapeutics for the Management of Adult Patients With Diabetes: Systematic Review and Meta-Analysis of Randomized Controlled Trials},
journal = {Journal of Medical Internet Research},
year = {2025},
volume = {27},
pages = {e70428},
doi = {10.2196/70428}
}
EUVIMED